Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus SLOW K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus SLOW K.
K-TAB vs SLOW-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
Adults: 600-2400 mg potassium chloride (8-32 mmol K+) orally per day in divided doses, usually 1-2 tablets twice daily. Maximum single dose: 20 mmol. Route: oral. Frequency: 1-4 times daily.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Not applicable; potassium is an electrolyte with no defined elimination half-life; distribution half-life ~2-4 hours
Renal (90% unchanged), fecal (10% as metabolites)
Primarily renal (>90%) as potassium ions; minimal biliary/fecal elimination (<5%)
Category C
Category C
Potassium Supplement
Potassium Supplement